Think Basis Inc. | Intelligence Report
The Growth Gap: Why Most Aesthetic Practice Acquisitions Underperform
And the 3 Operational Failures PE Firms Miss in Diligence
By Nick Dumitru, Think Basis Inc.
Executive Summary
Seventy-seven dermatology and aesthetics transactions closed in 2023. Eighty-five practice acquisitions completed. Over 50 publicly announced medspa deals per year in 2023 and 2024. KKR backed SkinSpirit. Sheridan Capital formed Ascend Plastic Surgery Partners. VSS Capital launched Olympus Cosmetic Group. The money is pouring in.
And most of it will underperform. A 40-year analysis of 40,000 acquisitions found 70-75% fail to create value.1 KPMG puts it at 83%.2 Bain says only 30% achieve their projected cost savings.3 In healthcare specifically, 7 of the 8 largest bankruptcies in 2023 were PE-backed companies, each carrying $500M+ in liabilities.4
The problem isn't the market. Aesthetic medicine is a $17B+ industry growing by more than $1B per year.5 The problem is what happens after close. PE firms measure EBITDA, payer mix, and provider productivity. They don't measure conversion rate, phone answer rate, or speed to lead. That's the growth gap. This report quantifies it and shows you where to find it before your next deal closes.
1. The Market Is Hot. The Results Are Not.
The numbers tell a clear story of acceleration. Dermatology and aesthetics deals climbed from 54 in 2021 to 66 in 2022 to 77 in 2023.6 Seventy-three percent of those were add-on acquisitions, not new platforms.6 Twenty-nine new platform deals launched from 2021 through September 2024.7 Ten-plus active PE-backed plastic surgery platforms now operate simultaneously.8
The multiples reflect that heat. Plastic surgery practices at $1M-$3M EBITDA trade at 7.3x. Dermatology platforms with medspa exposure command 12-15x. Scaled regional medspa chains hit 7x-12x. An MD-led medspa attached to a surgical center gets a 1-3x premium on top of that.9
Schweiger Dermatology acquired United Skin Specialists, then closed on California Skin Institute for $111.5M.10 Legacy derm platforms like Forefront and QualDerm are now buying plastic surgery practices and medspas to offer full-spectrum aesthetic services.11 The DSO model that consolidated dentistry is being replicated across aesthetics through MSOs.
But here's what those deal tombstones don't tell you.
70-75% of acquisitions fail to create value. In healthcare, that number may be worse.
Fortune/HBR, 40-year analysis of 40,000 acquisitions
McKinsey says 60% of deals fail to create value.12 KPMG says 83% fail to boost shareholder returns.2 The top three reasons: overpaying (42%), inadequate due diligence (31%), and poor post-merger integration (27%).1 First-time acquirers succeed 23% of the time. Serial acquirers with 10+ deals: 54%.1
In 2024 PE exits, revenue growth accounted for 71% of value creation.13 Two-thirds of total return for buyout deals from 2010-2021 came from multiple expansion and leverage, both of which are declining.13 Bain calls it "12 is the new 5": deals now require roughly 10-12% average annual EBITDA growth to generate a benchmark 2.5x return over five years.13
Financial engineering used to be enough. It's not anymore. And the firms that know this are outperforming. Funds that prioritize operational value creation achieve 2-3 percentage points higher IRR. Portfolio companies with operational improvement programs command 25-40% higher exit multiples.14
2. The 3 Operational Failures PE Firms Miss
You're measuring what the practice earned. You should be measuring whether it can keep earning.
Failure 1: The Conversion Gap
The median patient conversion rate for medical practices is 3.6%. Top performers convert at 21.1%. That's a 6x gap, and it sits in every practice you're evaluating.15
Read that again. Six times the revenue from the same lead volume. No additional marketing spend. No new channels. Just converting the patients who already raised their hand.
Where do those leads die? On the phone. Thirty-two percent of calls to a typical practice go unanswered.16 Eighty-five percent of callers who hang up will not call back. They call a competitor.16 Of the callers who do get through, 59% never book an appointment.15 The front desk is converting less than half the qualified leads it speaks to.
Healthcare has the slowest speed-to-lead of any industry: 2 hours and 5 minutes.
InfluxMD, 2025 Lead Conversion Crisis Report
It gets worse. Healthcare has the slowest average lead response time of any industry: 2 hours and 5 minutes.17 The average response time for leads that do get contacted is 47 hours.17 Only 27% of leads receive any contact at all.17
The data on speed is brutal. Leads contacted within 5 minutes are 21x more likely to convert than those contacted after 30 minutes. Within 10 minutes, the multiplier jumps to 70x versus waiting an hour.17
You're paying $100+ per cosmetic surgery lead.18 Average all-in patient acquisition cost for cosmetic surgery is $610.18 PAC has risen 56% since 2022.18 Those dollars buy interest. The front desk operation determines whether that interest becomes revenue. In most practices, it doesn't.
Failure 2: The Key Person Cliff
An aesthetic practice is its founding physician. The patients came for the doctor, not the brand. When the doctor leaves, the patients leave.
A March 2025 Health Affairs study of 200 ophthalmology practices and 1,980 clinicians found that PE-acquired practices saw physician turnover increase by 265% relative to baseline.19 A separate JAMA Health Forum study of 1,215 physicians found they were 16.5 percentage points more likely to leave within 2 years after the PE firm exited.20
The problem is worst with younger physicians. Among those under 40, the clinician replacement ratio was 2.28 in PE-acquired practices versus 1.08 in non-PE practices. PE practices had to replace more than double the physicians.21
Why do they leave? Administrative demands, loss of clinical autonomy, and pressure to meet financial targets.21 The financial incentives from acquisition often encourage older physicians to retire earlier than planned.22 Rollover equity was supposed to solve this alignment problem. The data says it doesn't.
PE-acquired practices saw physician turnover increase by 265%.
Health Affairs, March 2025 (200 practices, 1,980 clinicians)
This isn't just an HR problem. It's a revenue concentration problem. When the physician who brings in 40-60% of the practice's bookings walks, you don't get a gradual decline. You get a cliff. And standard diligence doesn't model it because it treats provider productivity as a trailing metric, not a retention risk.
Failure 3: The Revenue Growth Assumption
Revenue growth drove 71% of value creation in 2024 PE exits.13 That means your thesis depends on growth. But your diligence is measuring the wrong thing.
Standard diligence looks at EBITDA, margins, payer mix, procedure volume, accounts receivable. All backward-looking. All telling you what the practice earned last year. None of them tell you whether it can grow.
Eighty-three percent of PE professionals believe their own due diligence approach needs significant improvement.23 Twenty-eight percent of healthcare marketers can't measure marketing ROI at all.24 Twenty-five percent of ad clicks are fraudulent.15 And most practices operate with disconnected systems that make end-to-end tracking from lead to collected revenue impossible.
Here are the six metrics that predict post-acquisition growth. Ask for them during diligence. If the practice can't produce them, that's your answer.
| Metric | Why It Predicts Growth | Benchmark |
|---|---|---|
| Lead conversion rate | Median 3.6%, top 21.1%. Directly maps to revenue from existing spend. | Target >10% |
| Phone answer rate | 32% unanswered = 32% of leads going to competitors. Unrecoverable. | Target >95% |
| Speed to lead | 5-min response = 21x higher conversion. Industry avg is 2hr 5min. | Target <5 min |
| Patient acquisition cost | Ranges from $25 (SEO) to $610 (cosmetic all-in). Without attribution, can't tell which channels work. | Know by channel |
| Staff retention rate | 265% physician turnover spike post-acquisition. Models break when providers leave. | Track pre/post |
| Marketing attribution | 28% of marketers can't measure ROI. Without closed-loop tracking, you're flying blind. | Revenue matchback |
Financial diligence tells you what a practice earned. Operational diligence tells you whether it can keep earning, and whether it can grow. The first is standard. The second is where the alpha is.
3. What Top Performers Measure Instead
The gap between standard PE diligence and what actually predicts practice growth isn't theoretical. It's measurable.
| Standard PE Diligence | Operational Growth Diligence |
|---|---|
| EBITDA and margins | Lead-to-patient conversion rate |
| Revenue and growth rate | Phone answer rate and call handling quality |
| Patient volume | Speed-to-lead response time |
| Payer mix | Patient acquisition cost by channel |
| Provider productivity (RVUs) | Provider-dependency concentration |
| Accounts receivable | Marketing attribution accuracy |
| Debt service coverage | Staff retention rate (pre and post-close) |
| Real estate and lease terms | No-show and cancellation rate |
The left column tells you what the practice earned yesterday. The right column tells you what it will earn tomorrow. Both matter. But only one predicts whether your growth thesis will hold.
The compound math of small operational fixes
Patient Prism analyzed 7.37 million calls in 2024 and identified 1.5 million lost opportunities across 12.5 million monitored calls in 2025.25 Only 36% of those received follow-up. The ones that did converted 87,000 new patients.25
Here's the math that matters for your portfolio: recovering just 5 missed patients per month at $2,000 lifetime value each adds $120,000 per year in revenue.25 Per location. With no additional marketing spend.
Now multiply that across a platform with 8, 15, or 40 locations. A 10-provider aesthetic practice generating $5M in revenue with a 3.6% conversion rate is leaving $10M+ on the table. Moving from 3.6% to 10% conversion, still well below top-performer benchmarks, doesn't require more ad budget. It requires answering the phone within 60 seconds, following up within 5 minutes, and training the front desk to close.
Cost of that operational fix: a fraction of the $1M+ additional marketing spend most PE operators default to when growth stalls post-acquisition.
Recovering 5 missed patients per month adds $120,000/year in revenue. Per location. No additional ad spend.
Patient Prism, 7.37M calls analyzed (2024)
Organic search converts 76.9% of prospects to patients. Paid search converts 64.2%.18 Fewer than 40% of practices have a structured referral program, despite referrals being the highest-converting and lowest-cost acquisition source.18
The alpha in aesthetic practice acquisitions isn't in financial engineering. It's in the operations nobody checks during diligence.
One Diagnostic Question
Before your next acquisition closes, ask one question: What is the practice's lead-to-patient conversion rate?
If they can answer it, you've found a practice that understands its growth mechanics. If they can't, you've found the growth gap.
That gap is either your risk or your opportunity. It depends on whether you see it before you close.
Sources
- Fortune, "We analyzed 40,000 M&A deals over 40 years" (2024). fortune.com
- KPMG, M&A Deal Outcomes Report (2023). Acquisition Stars compilation
- Bain & Company, Private Equity Report (2024). bain.com
- PE Stakeholder Project, "PE Healthcare Bankruptcies on the Rise" (2023). pestakeholder.org
- AmSpa, 2024 Medical Spa State of Industry Report. americanmedspa.org
- Practical Dermatology, "The Dermatology & Aesthetics M&A Market" (March 2025). practicaldermatology.com
- PitchBook, "Private equity raises bets on Botox-dealing medspas" (2024). pitchbook.com
- Physician Growth Partners, "Plastic Surgery PE Fall 2023." physiciangrowthpartners.com
- First Page Sage, Healthcare EBITDA Valuation Multiples (2025); Scope Research, Med Spa Valuation Multiples (2025); Breakwater M&A, Medical Spa Valuation (2026). firstpagesage.com, scoperesearch.co, breakwaterma.com
- HCAI Material Change Notice, Schweiger/CSI acquisition filing. hcai.ca.gov
- Physician Growth Partners, "Dermatology PE Fall 2025." physiciangrowthpartners.com
- McKinsey, "Bridging Private Equity's Value Creation Gap." mckinsey.com
- Bain & Company, Private Equity Report 2026. bain.com
- McKinsey, PE Value Creation; CLA, "Operational Value Creation Over Financial Engineering." mckinsey.com, claconnect.com
- InfluxMD, "The Medical Practice Lead Conversion Crisis" (2025); "Lead Conversion Rates." influxmd.com
- CallRail, Healthcare Marketing Statistics (2025); Keona Health, Missed Calls in Healthcare. callrail.com, keonahealth.com
- InfluxMD, Lead Conversion Crisis 2025. influxmd.com
- First Page Sage, Average Patient Acquisition Cost (2026); Plastic Surgery Lead Gen Statistics (2026). firstpagesage.com
- Health Affairs, "Physician Turnover in PE Practices" (March 2025). doi:10.1377/hlthaff.2024.00974
- JAMA Health Forum, "PE Practice Sales and Physician Turnover" (Feb 2025). jamanetwork.com
- Medical Economics, "Physician Turnover Surges in PE-Acquired Practices." medicaleconomics.com
- Fierce Healthcare, "Physician Hiring/Turnover After PE Acquisition." fiercehealthcare.com
- Hedge Think, "Operational Due Diligence Checklist PE Funds Miss." hedgethink.com
- Freshpaint, "Measure Healthcare Marketing ROI"; Anzolo Medical, Healthcare Marketing Attribution (2026). freshpaint.io, anzolomed.com
- Patient Prism, Healthcare Call Tracking Metrics (2026); Healthcare Call Center Metrics (2026). patientprism.com